



The Chemours Company

Citi Basic Materials Conference

November 29, 2016

Safe Harbor Statement

This presentation contains forward-looking statements, which often may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates,” “targets,” “anticipates” or other words of similar meaning. These forward-looking statements address, among other things, our anticipated future operating and financial performance, business plans and prospects, transformation plans, resolution of environmental liabilities, litigation and other contingencies, plans to increase profitability, our ability to pay or the amount of any dividend, and target leverage that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements, as further described in our filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the fiscal year ended December 31, 2015. Chemours undertakes no duty to update any forward-looking statements.

This presentation contains certain supplemental measures of performance that are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). These Non-GAAP measures include Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA and Free Cash Flow, which should not be considered as replacements of GAAP. Free Cash Flow is defined as Cash from Operations minus cash used for PP&E purchases. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA and Free Cash Flow to evaluate the Company’s performance excluding the impact of certain non-cash charges and other special items in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Historical results prior to July 1, 2015 are presented on a stand-alone basis from DuPont historical results and are subject to certain adjustments and assumptions as indicated in this presentation, and may not be an indicator of future performance.

Additional information for investors is available on the company’s website at investors.chemours.com.

The Chemours Company at a Glance



Sales ⁽¹⁾ :	\$5,438
Adj. EBITDA ⁽¹⁾ :	\$715
% margin:	13%

Titanium Technologies

Sales ⁽¹⁾ :	\$2,331
Adj. EBITDA ⁽¹⁾ :	371
% margin:	16%

- Titanium dioxide (TiO₂) is a pigment used to deliver whiteness, opacity, brightness and protection from sunlight
- **#1 global producer of TiO₂ by capacity, sales and profitability**

Fluoroproducts

Sales ⁽¹⁾ :	\$2,210
Adj. EBITDA ⁽¹⁾ :	413
% margin:	19%


- Products for high performance applications across broad array of industries, including refrigerants, propellants and industrial resins
- **#1 global producer of both fluorochemicals and fluoropolymers**

Chemical Solutions


Sales ⁽¹⁾ :	\$897
Adj. EBITDA ⁽¹⁾ :	46
% margin:	5%

- Chemicals used in gold production, oil refining, agriculture, industrial polymers and other industries
- **#1 producer in Americas of sodium cyanide**

Sales By Geography⁽²⁾



Sales By Product⁽²⁾



Dollars in millions

⁽¹⁾ Data represents last twelve months ending September 30, 2016

⁽²⁾ Geographic and product data reflect full year 2015 net sales; does not reflect impact of divestitures




Adjusted EBITDA includes corporate and other charges which are not reflected in individual segment Adjusted EBITDA. See reconciliation of Adjusted EBITDA in Appendix.

Fluoroproducts Business Overview

Business Overview

- Supplies products for high performance applications across broad array of industries
- #1 in Fluoroproducts globally
 - Fluorochemicals: #1 in refrigerants, #1 in propellants, #3 in foaming agents
 - Fluoropolymers: #1 in industrial resins, #1 in fluoropolymer specialties
- Key Brands include Teflon™, Freon™, Opteon™, Krytox™, Nafion™, Viton™

Chemours is #1 in Fluoroproducts Globally⁽²⁾



Source: Company filings and data, Fluoroproducts: Company filings and Management estimates


(1) Reflects full year 2015 segment net sales

(2) Fluorochemicals and fluoropolymers market share statistics based on 2015 internal revenue estimates and company filings

(3) Includes 100% contribution from the DuPont-Mitsui Fluorocarbon Company joint venture

- **Fluorochemicals** – mainly refrigerants, propellants, and foam expansion agents
- **Fluoropolymers** – mainly industrial resins and downstream products & coatings
- **Key End Markets** – AC, refrigeration, automotive, aerospace, wire & cable, consumer electronics and telecommunications

The History of Innovation in Fluoropolymers



Chemours has invented most of the major fluoropolymer chemistries

Fluoropolymers Diverse and Broad End Use Applications



Consumer Electronics



Power & Energy



Automotive



Medical



Semicon



Fabrics



Consumer



Telecommunications



Wearable Technology

Chemours provides tailored solutions for complex and demanding applications

The History of Fluorochemicals



Freon™ (CFC) developed, making widespread use of refrigerators and air conditioning possible; also serves as a propellant in aerosol sprays

Montreal Protocol

Produced last CFCs in developed countries

ISCEON™ (HFC) launched as near drop-in replacement for HCFC refrigerants

Opteon™ 1100 low GWP foam blowing agent developed

1930s

1970s

1987

1990

1995

1997

2005

2011

2014

2016

HFCs identified as replacement to CFCs

Address ozone depletion with the development of non-CFC refrigerants (Suva™) and propellants (Dymel™)

Kyoto Protocol

Breakthrough HFO chemistry leads to Opteon™ for use in mobile and stationary refrigeration

Kigali Agreement



Chemours has been the center of all relevant discovery for fluorochemicals



Chemours™ CFCs = Chlorofluorocarbons; HCFCs = Hydrochlorofluorocarbons; HFCs = Hydrofluorocarbons; HFOs = Hydrofluoro-Olefins GWP = global warming potential

Regulatory Drivers of Fluorochemicals

Montreal Protocol (1987)

- **Goal:** to phase out ozone depleting chemicals (ODCs) including CFCs and HCFCs
 - Signed by 24 countries
 - Phase out CFC use and production by 1996
 - Freeze consumption and production of HCFCs in 2013; begin reducing in 2015

Kyoto Protocol (1997)

- **Goal:** to reduce greenhouse gas (GHG) emissions
 - Implemented mandatory targets on GHGs for world's leading economies
 - Commitments vary from nation to nation

Kigali Amendment (2016)

- **Goal:** to phase down HFCs
 - Developed countries to freeze production & consumption of HFCs by 2018; begin reducing in 2019
 - Developing countries to freeze HFC use by 2024
 - World's hottest countries (India, Pakistan, Iran, Saudi Arabia, Kuwait) to freeze HFC use by 2028

United States Drivers:

- **2017-2019:** Delist specific HFCs for new commercial refrigeration
- **2017-2020:** Delist HFC-245 (foam)
- **2017-2021:** Car OEM's taking advantage of CO₂ carbon credits
- **2021:** EPA SNAP delist of HFC-134a in 2021 (model year 2020)

European Union Drivers:

- **2011-2017:** European MAC directive full enforcement in 2017 for Mobile AC <150 GWP
- **2015-2030:** EU F-gas cap & phase down reduces HFC's 79% of baseline
- **2018:** HFC Cap reduction of 37% drives move to low-GWP Opteon™ solutions
- **2020:** EU F-Gas GWP limit for commercial refrigeration for new & service equipment

Other Countries Drivers:

- **2018:** Turkey MAC Directive effective January 1
- **2018-2019:** Australia considering low GWP requirement for MAC
- **2022:** Japan Adoption of MAC, with voluntary target of 40% by 2020

Opteon™ - Mobile Air Conditioning (MAC)

Mobile Air Conditioning adoption on track in European Union, United States and other markets

2017:

- European MAC Directive in full force

2018:


- Turkey MAC Directive in full force
- Australia regulation under review (possibility for MAC requirements)

2017-2021:

- US OEMs ramp up use of HFO technology to take advantage of CO2 credits under US EPA GHG Standard
- US and Canada ban HFC technology for new MAC in model year 2021 (calendar year 2020)
- South Korea OEMs ramp up use of HFO technology under South Korea GHG Standard

2022:

- Japan use of low GWP mandatory for MAC by model year 2023 (calendar year 2022); voluntary adoption target of 40% by 2020



Mobile Air Conditioning regulations driving Opteon™ well into next decade



Chemours™

Source: Company filings and data, Fluorochemicals: Company filings and Management estimates
Note: Term definitions can be found in appendix

Patented HFO-blends for **Stationary Refrigeration** and **Air Conditioning** adoption increasing

- EU F-Gas: 37% CO₂ equivalent reduction by 2021
- US EPA SNAP delist of specific HFCs for new commercial refrigeration equipment

Opteon™ 1100 Foaming Agent applications are seeing early adoption; expect to ramp up in next few years

- Provides zero ozone depletion and low global warming potential
- Improves energy efficiency for various applications



Stationary Refrigeration




Stationary Air Conditioning



Foam Blowing Agents

Opteon™ Expansion in Progress

- Creates the world's largest facility for manufacturing hydrofluoroolefins (HFOs)
- Allows Chemours to meet customer needs in the face of exponential growth in demand for Opteon™ products
- Utilizes unique process technology that is expected to be lowest cost producer of HFOs



As Opteon™ mix increases, expect margin enhancement

Fluoroproducts Market Dynamics and Opportunities

Fluoropolymers

- ↑ Strong collaborations in key end markets provide solid base of demand and growth opportunities
- ↑ Heritage of innovation and new application development expected to enhance our portfolio and move into adjacent markets
- ↑ Unlocking value through differential management
- ↔ Demand conditions driven by GDP growth in North America, Europe offset by slower growth in China
- ↓ Increasing competition

Fluorochemicals

- ↑ Global Warming Potential phasedown regulations in developed markets, expanding globally
- ↑ Market adoption ramp up of IP-protected HFO portfolio only in beginning stages
- ↑ Demand conditions driven by energy efficiency needs
- ↓ Regulatory volume reductions for base refrigerants, partially offset by higher prices
- ↓ Excess capacity within base business

Technology, application development & cost reductions enhance profitability

Appendix

Definitions

SNAP: Significant New Alternatives Policy

GHG: Greenhouse Gas

F-Gas: Fluorinated Greenhouse Gases

ODP: Ozone Depletion Potential

GWP: Global Warming Potential

MAC: Mobile Air Conditioning

CFC: Chlorofluorocarbon

HCFC: Hydrochlorofluorocarbon

HFC: Hydrofluorocarbon

HFO: Hydrofluoro-Olefins

(\$ in millions unless otherwise noted)

SEGMENT NET SALES (UNAUDITED)

(dollars in millions)

	LTM				
	3Q16	3Q16	2Q16	1Q16	4Q15
Titanium Technologies	\$ 2,331	\$ 625	\$ 596	\$ 521	\$ 589
Fluoroproducts	2,210	591	573	531	515
Chemical Solutions	897	182	214	245	256
TOTAL NET SALES	\$ 5,438	\$ 1,398	\$ 1,383	\$ 1,297	\$ 1,360

SEGMENT ADJUSTED EBITDA (UNAUDITED)

(dollars in millions)

	LTM				
	3Q16	3Q16	2Q16	1Q16	4Q15
Titanium Technologies	\$ 371	\$ 144	\$ 111	\$ 54	\$ 62
Fluoroproducts	413	143	105	85	80
Chemical Solutions	46	9	11	10	16
Corporate & Other	(115)	(28)	(40)	(21)	(26)
TOTAL ADJUSTED EBITDA	\$ 715	\$ 268	\$ 187	\$ 128	\$ 132

SEGMENT ADJUSTED EBITDA MARGIN (UNAUDITED)

	LTM				
	3Q16	3Q16	2Q16	1Q16	4Q15
Titanium Technologies	15.9%	23.0%	18.6%	10.4%	10.5%
Fluoroproducts	18.7%	24.2%	18.3%	16.0%	15.5%
Chemical Solutions	5.1%	4.9%	5.1%	4.1%	6.3%
Corporate & Other	0.0%	0.0%	0.0%	0.0%	0.0%
TOTAL CHEMOURS	13.1%	19.2%	13.5%	9.9%	9.7%

* Note summation of individual quarters may not sum to the year-to-end (YTD), last twelve months (LTM) or full year amounts due to rounding.

GAAP Net Income (Loss) to Adjusted EBITDA and Adjusted Net Income Reconciliations

(\$ in millions except per share unless otherwise noted)

	Three months ended				Three months ended	
	September 30,				June 30,	
	2016		2015		2016	
	\$ amounts	\$ per share	\$ amounts	\$ per share	\$ amounts	\$ per share
Net income (loss) attributable Chemours	\$ 204	\$ 1.12	\$ (29)	\$ (0.16)	\$ (18)	\$ (0.10)
Non-operating pension and other postretirement employee benefit costs	(5)	(0.03)	(10)	(0.06)	(7)	(0.04)
Exchange losses (gains)	17	0.09	(44)	(0.24)	14	0.08
Restructuring charges	14	0.08	139	0.77	9	0.05
Asset related charges ¹	46	0.25	70	0.39	63	0.35
(Gain) loss on sale of assets or business	(169)	(0.93)	-	-	1	0.01
Transaction costs ²	2	0.01	-	-	12	0.07
Legal and other charges ³	5	0.03	-	-	13	0.07
Benefit from income taxes relating to reconciling items ⁴	(2)	(0.01)	(53)	(0.29)	(38)	(0.21)
Adjusted Net Income	\$ 112	\$ 0.62	\$ 73	\$ 0.40	\$ 49	\$ 0.27
Net income attributable to noncontrolling interests	-	-	-	-	-	-
Interest expense	51	-	51	-	50	-
Depreciation and amortization	73	-	70	-	73	-
All remaining (benefit from) provision for income taxes	32	-	(25)	-	15	-
Adjusted EBITDA	\$ 268	-	\$ 169	-	\$ 187	-
Weighted average number of common shares outstanding - Basic ²	181,596,161	-	180,968,049	-	181,477,672	-
Weighted average number of common shares outstanding - Diluted ^{2,3}	183,528,556	-	181,886,729	-	182,592,517	-
Earnings per share, basic	\$ 1.12	-	\$ (0.16)	-	\$ (0.10)	-
Earnings per share, diluted	\$ 1.11	-	\$ (0.16)	-	\$ (0.10)	-
Adjusted earnings per share, basic ²	\$ 0.62	-	\$ 0.40	-	\$ 0.27	-
Adjusted earnings per share, diluted ^{2,3}	\$ 0.61	-	\$ 0.40	-	\$ 0.27	-

¹ The three and nine months ended September 30, 2016 includes \$46 million pre-tax asset impairment of our Pascagoula Aniline facility and other asset write-offs. The nine months ended September 30, 2016 also included \$58 million pre-tax asset impairment in connection with the sale of the Sulfur business and other asset write-offs, which were recorded in the second quarter of 2016. The three and nine months ended September 30, 2015 includes \$25 million of goodwill impairment and \$45 asset impairment of RMS facility. All of these changes are recorded in the Chemical Solutions segment.

² Includes accounting, legal and bankers transaction fees incurred related to the Company's strategic initiatives, which includes pre-sale transaction costs incurred in connection with the sales of C&D and Sulfur businesses.

³ Includes litigation settlements, water treatment accruals related to PFOA, and lease termination charges.

⁴ Total of provision for (benefit from) income taxes reconciles to the amount reported in the Interim Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015.

GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA

(\$ in millions unless otherwise noted)

	LTM		YTD			
	3Q16	2016	3Q16	2Q16	1Q16	4Q15 ³
Net income (loss) attributable to Chemours	\$ 151	\$ 237	\$ 204	\$ (18)	\$ 51	\$ (86)
Non-operating pension and other postretirement employee benefit costs (income)	(27)	(19)	(5)	(7)	(7)	(8)
Exchange losses (gains)	65	37	17	14	6	28
Restructuring charges	126	41	14	9	17	85
Asset related charges	112	109	46	63	-	3
(Gain) loss on sale of assets or business	(249)	(258)	(169)	1	(89)	9
Transaction costs	27	18	2	12	3	9
Legal and other charges	32	24	5	13	5	8
(Benefit from) provision for income taxes relating to reconciling items ¹	(62)	(16)	(2)	(38)	25	(46)
Adjusted Net Income	\$ 175	\$ 173	\$ 112	\$ 49	\$ 11	\$ 2
Net income attributable to noncontrolling interests	-	-	-	-	-	-
Interest expense, net	210	157	51	50	57	53
Depreciation and amortization	278	212	73	73	66	66
All remaining (benefit from) provision for income taxes ¹	52	41	32	15	(6)	11
Adjusted EBITDA	\$ 715	\$ 583	\$ 268	\$ 187	\$ 128	\$ 132
Adjusted earnings per share, basic ²	\$ 0.98	\$ 0.95	\$ 0.62	\$ 0.27	\$ 0.06	\$ 0.03
Adjusted earnings per share, diluted ²	\$ 0.97	\$ 0.94	\$ 0.61	\$ 0.27	\$ 0.06	\$ 0.03

¹ Total of provision for (benefit from) income taxes reconciles to the amount reported in the interim consolidated statement of operations for the three months ended June 30, 2016, March 31, 2016, September 31, 2015, June 30, 2015, March 31, 2015 and year ended December 31, 2015.

² On July 1, 2015, E.I. du Pont de Nemours and Company distributed 180,966,833 shares of Chemours' common stock to holders of its common stock. Basic and diluted earnings per common share for the periods on or prior to June 30, 2015 were calculated using the number of shares distributed on July 1, 2015.

³ Certain adjustments of prior year's data have been made to conform to current year presentation.

* Note summation of individual quarters may not sum to the year-to-end (YTD), last twelve months (LTM) or full year amounts due to rounding.



Chemours™